

ALLIGATOR BIOSCIENCE ANNOUNCES RESIGNATION OF MALIN CARLSSON AS CHIEF OPERATING OFFICER

Lund, Sweden, August 17, 2023 - Alligator Bioscience (Nasdaq Stockholm: **ATORX**) today announces the resignation of Malin Carlsson as the company's Chief Operating Officer (COO). Dr Carlsson will leave her role at the end of October to assume an executive role in a global pharma company. Dr Carlsson's responsibilities will be transferred to other members of the Management team.

*"We would like to thank Malin for the dedication she has shown during her time at Alligator and in particular her valuable contribution to our mitazalimab program, which is continuing to make excellent clinical progress," said **Søren Bregenholt, CEO of Alligator Bioscience**. "Malin's experience in immunology and drug development, and the new role she is about to embark upon, demonstrate how Alligator is able to attract talents in the biotech industry, and we wish her the very best for the future."*

Alligator recently announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study evaluating the company's lead asset mitazalimab in combination with chemotherapy, mFOLFIRINOX, in 1st line metastatic pancreatic cancer. The study continues to progress well and remains on track for top-line readout in early Q1 2024.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

LifeSci Advisors
Investor Relations
Guillaume van Renterghem
E-mail: gvanrenterghem@lifesciadvisors.com
Phone: +41 (0) 76 735 01 31

PRESS RELEASE

17 August 2023 08:00:00 CEST



About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer